Literature DB >> 28296873

Combined Ex Vivo Organ Perfusion and Mesenchymal Stem Cells Transplantation.

Mohamed S A Mohamed1.   

Abstract

Background: The importance of solid organ transplants is increasing due to the increasing incidence of end-stage organ diseases. With the limitations facing the recruitment of the suitable grafts, ex vivo organ perfusion (EVOP) techniques have been developed to increase the graft acceptance rates and improve the clinical outcomes. Methodology: The role of mesenchymal stem cells (MSCs) in this regard is not limited to the regenerative ability. MSCs have proved their ability to effectively modulate the immune response and inflammation. Accordingly, the idea of the combined ex vivo organ perfusion and MSCs transplant came to focus. This manuscript reviews some points that should be considered, while applying this technique.
Conclusion: The combined EVOP-MSCs is a therapeutic technique that should be soon applied in the practice of solid organ transplants. However, certain remarks should be considered on the pre-clinical levels before taking the studies further into the clinical levels. Although the present report will focus on the lung transplant, the ideas and the remarks are also to be considered for all other solid organ transplants, such as heart, liver and kidney.

Entities:  

Keywords:  Cell therapy; Ex vivo perfusion; Mesenchymal stem cells; Organ preservation; Solid organ transplant

Mesh:

Year:  2016        PMID: 28296873

Source DB:  PubMed          Journal:  J Stem Cells        ISSN: 1556-8539


  2 in total

1.  The future of organ-oriented research and treatment.

Authors:  Qiang Zhao; Yu Nie; Zhiyong Guo; Xiaoshun He
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

2.  Human ex vivo lung perfusion: a novel model to study human lung diseases.

Authors:  Nayra Cárdenes; John Sembrat; Kentaro Noda; Tyler Lovelace; Diana Álvarez; Humberto E Trejo Bittar; Brian J Philips; Mehdi Nouraie; Panayiotis V Benos; Pablo G Sánchez; Mauricio Rojas
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.